CoChat
Sign Up
Cited by 192Growth Hormone and Insulin-like Growth FactorsThyroid Disorders and TreatmentsPituitary Gland Disorders and Treatments

Effects of Growth Hormone Therapy on Thyroid Function of Growth Hormone-Deficient Adults with and without Concomitant Thyroxine-Substituted Central Hypothyroidism*

JøRGENSEN, J. O. L., PEDERSEN, S. A., LAURBERG, P., WEEKE, J., SKAKKEBÆK, N. E., CHRISTIANSEN, J. S.·1989·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jcem-69-6-1127
Open this paper in CoChat — free account

Abstract

Administration of human GH to GH-deficient patients has yielded conflicting results concerning its impact on thyroid function, ranging from increased resting metabolic rate to induction of hypothyroidism. However, most studies have been casuistic or uncontrolled and have used pituitary-derived GH of varying purity, often contaminated with TSH. Therefore, we conducted a double blind, placebo-controlled cross-over study of the effect of 4 months of biosynthetic human GH therapy (Norditropin; 2 IU/m2.day) on thyroid function in GH-deficient adults (8 females and 14 males; mean +/- SE age, 23.8 +/- 1.2 yr). One group (I) was euthyroid without T4 substitution (n = 13), whereas the other (group II) received T4 (n = 9). Serum T4 (nanomoles per L) decreased in both groups after GH treatment [group I, 100 +/- 8 (mean +/- SE) vs. 89 +/- 8 (P less than 0.01); group II, 145 +/- 18 vs. 115 +/- 10 (P less than 0.05)]. Conversely, GH treatment caused an increase in serum T3 (nanomoles per L) in both groups [group I, 1.9 +/- 0.1 vs. 2.0 +/- 0.1 (P less than 0.1); group II, 1.7 +/- 0.1 vs. 1.9 +/- 0.1 (P less than 0.05)]. Similar changes were seen in serum free T4 and T3. The serum T3 level during the placebo period of group I was significantly lower than that in an age-matched reference group (P less than 0.02). Serum rT3 (nanomoles per L) was low in group I and decreased significantly, as in group II, after GH treatment [group I, 0.26 +/- 0.02 (placebo) vs. 0.20 +/- 0.02 (GH; P less than 0.01); group II, 0.38 +/- 0.05 (placebo) vs. 0.29 +/- 0.02 (GH; P less than 0.01)]. Serum TSH decreased in both groups during GH therapy, though not significantly. Serum thyroglobulin was unaltered and did not differ from that in the reference group. In conclusion, our data are consistent with a GH-induced enhancement of peripheral deiodination of T4 to T3. GH thus seems to play an important role, either directly or indirectly, in the regulation of peripheral T4 metabolism.

Integrity signals

Registry

Crossref · 10.1210/jcem-69-6-1127

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
JøRGENSEN, J. O. L., PEDERSEN, S. A., LAURBERG, P., WEEKE, J., SKAKKEBÆK, N. E., & CHRISTIANSEN, J. S.
Affiliations
Aarhus University (DK)
ORCID
JøRGENSEN, J. O. L.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
1989-12
Volume
69
Issue
6
Pages
1127-1132
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jcem-69-6-1127
OpenAlex
W2007272731
Cited by
192
References
39
Citations by year
2026: 1 · 2025: 1 · 2023: 1 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 3 · 2018: 5 · 2017: 3 · 2016: 5 · 2015: 1 · 2014: 5 · 2013: 4 · 2012: 3
FWCI
4.94
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
Keywords
growth hormone therapy, growth hormone deficiency, central hypothyroidism, thyroid function, thyroxine-binding globulin, reverse T3, thyroid-stimulating hormone, triiodothyronine, thyroxine, free thyroxine, resting metabolic rate, pituitary-derived growth hormone
MeSH terms
Adult, Clinical Trials as Topic, Female, Humans, Hypothyroidism, Male, Growth Hormone, Thyroglobulin, Thyroid Gland, Thyrotropin, Thyroxine, Triiodothyronine, Triiodothyronine, Reverse

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review